- Product Revenue Increased 81 Percent; Tests Delivered Grew 69 Percent
Year over Year -
- Net Loss Continued to Narrow -
- Company Updates 2008 Guidance -
- Conference Call Today at 4:30 p.m. ET -
REDWOOD CITY, Calif., Aug. 5 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX) today reported financial results and business progress for the quarter ended June 30, 2008.
Total revenue increased to $27.8 million in the second quarter of 2008 compared to $14.7 million in the second quarter of 2007. Product revenue from the Oncotype DX(R) breast cancer assay was $26.3 million in the second quarter of 2008, an increase of 81 percent compared to $14.6 million in the second quarter of 2007, the result of continued growth in adoption and reimbursement. Contract revenue was $1.5 million in the second quarter of 2008, compared to $135,000 in the second quarter of 2007, reflecting continued collaboration with pharmaceutical partners to explore the development of tests for predicting benefit from certain targeted therapies.
"We believe the increasing impact of personalized medicine and our investment in Oncotype DX are reflected not only in our strong revenue and growth in tests delivered, but also in the narrowing of our net loss in the second quarter," said Randy Scott, Ph.D., chairman and chief executive officer of Genomic Health. "While we work to further reduce our net loss, we will continue to invest in our product pipeline and expand our commercial efforts outside of the United States, which we expect to be important components of future growth."
Additional Second Quarter 2008 Financial Results
During the s492 71,166
Total liabilities and stockholders'
equity $86,588 $87,929
The condensed consolidated balance sheet at December 31, 2007 has been
derived from the audited consolidated financial statements at that date
included in the Company's Form 10-K for the fiscal year ended December 31,
2007.econd quarter of 2008, approximately 51 percent of product revenue was recorded on an accrual basis and recognized at the time the test results were delivered, reflecting established payment patterns from payors with coverage policies in place.
Cost of product revenue was $6.9 million in the second quarter of 2008, compared to $4.2 million for the second quarter of 2007. Research and development expenses for the second quarter of 2008 were $7.3 million, compared to $5.2 million for the same period in 2007. Selling and marketing and general and administrative expenses for the second quarter of 2008 were $18.1 million, compared to $12.9 million for the same period in 2007. Included in second quarter 2008 operating expenses was $2.3 million of stock-based compensation expense, compared to $1.5 million in the same period in 2007.
Net loss was $4.1 million in the second quarter of 2008, compared to $7.2 million in the second quarter of 2007. Basic and diluted net loss per share was $0.15 in the second quarter of 2008, compared to a net loss per share of $0.28 in the second quarter of 2007.
Financial Results for Six Months Ended June 30, 2008
Total revenue for the six months ended June 30, 2008 was $51.2 million, compared to $28.8 million for the first six months of 2007. Product revenue for the six months ended June 30, 2008 was $49.7 million, compared to $27.7 million for the first six months of 2007. Contract revenue constituted the balance of revenue for the first six months of 2008 and 2007.
Cost of product revenue for the six months ended June 30, 2008 was $12.7 million, compared to $8.0 million for the comparable period in 2007. Research and development expenses for the first six months of 2008 were $13.7 million, compared to $10.4 million in the first six months of 2007. Selling and marketing and general and administrative expenses for the first six months of 2008 were $36.3 million, compared to $25.2 million in the first six months of 2007. The increase in expenses includes stock-based compensation expense of $4.5 million in the first six months of 2008 compared to $2.8 million for the same period in 2007.
Net loss for the six months ended June 30, 2008 was $10.7 million, compared to $14.0 million for the first six months of 2007. Basic and diluted net loss per share was $0.38 for the six months ended June 30, 2008, compared to a net loss per share of $0.55 for the first six months of 2007.
Cash and Cash Equivalents
Cash and cash equivalents and investments at June 30, 2008 were $60.6 million compared to $65.4 million at March 31, 2008 and $68.4 million at December 31, 2007.
Updated 2008 Outlook and Financial Guidance
The company is providing the following revised guidance for the full
year ending December 31, 2008:
-- Increasing expected test results delivered to 38,000 to 40,000 test
results, from previous guidance of 34,000 to 37,000 test results.
-- Projecting total revenue in a range between $105 million and $110
million, compared to previous guidance of $100 million to $110 million,
with an expectation that full-year revenue may be at the higher end of
-- Continuing to expect net loss of $15 million to $20 million for 2008,
with the net loss narrowing in the second half of 2008 as compared to
the first half of 2008.
Recent Highlights and Accomplishments
Physician Usage and Adoption
-- More than 9,690 test results were delivered in the second quarter of
2008, compared to more than 5,750 test results delivered in the second
quarter of 2007.
-- More than 18,850 test results were delivered in the first half of 2008,
compared to more than 11,200 test results delivered in the first half
-- More than 65,000 Oncotype DX test results have been delivered to
Peer-Reviewed Publications and Medical Meeting Presentations
-- The Journal of Clinical Oncology published a study online showing that
the Oncotype DX Recurrence Score provides additional prognostic
information in patients with early-stage breast cancer beyond that
derived from Adjuvant! Online, an online tool that evaluates clinical
variables to help physicians and patients assess the risks and benefits
of getting additional therapy after surgery.
-- Two abstracts were accepted for presentation at the ASCO Breast Cancer
Symposium in September of 2008.
-- The Journal of Clinical Oncology published results of a study
demonstrating the utility of Oncotype DX in measuring quantitative gene
expression for ER and PR status, indicating that quantitative RT-PCR,
as performed in the Oncotype DX breast cancer assay, is a reliable
method for determining hormone receptor status in breast cancer.
-- Presented results from two initial studies with collaborators that
could lead to the development of new tests for predicting benefit from
certain targeted therapies in cancer, at the 2008 ASCO meeting in June.
Reimbursement Progress for Oncotype DX
-- In June, Palmetto GBA, the company that will replace National Heritage
Insurance Company (NHIC) as the Medicare administrative contractor,
posted local coverage decisions for its jurisdiction that included
Oncotype DX. This coverage decision follows the identical criteria
previously set forth by NHIC. We expect to begin processing claims with
Palmetto in September of 2008.
-- Gained coverage for over 6.9 million additional lives for access to
o Blue Cross Blue Shield plans of Louisiana, Mississippi and
Northeastern Pennsylvania established policies covering approximately
2.3 million lives.
o Group Health Incorporated and HIP Health Plan of New York established
policies covering approximately 4.6 million lives.
-- Targeting inclusion of quantitative HER2 scores in all Oncotype DX
reports by the end of 2008.
-- Conducting a study using Oncotype DX in breast cancer patients treated
with aromatase inhibitors with the goal of reporting results this year.
-- Received first trial specimens for our clinical validation study, which
we expect to begin in the second half of 2008.
-- Received milestone payment from Bristol-Myers Squibb related to Genomic
Health's program to identify genes to predict response to cetuximab
-- Established collaborators and identified sources of clinical samples
to further our prostate and lung cancer programs.
-- Began gene identification work to develop a prognostic test for
patients with renal cell carcinoma, clear cell type, under the Pfizer
collaboration announced in January of 2008.
-- Initiated a study supporting Japanese investigators as they gain
clinical experience with Oncotype DX for early-stage breast cancer
-- Processing samples from patients in Canada, Ireland and Peru enrolled
in the National Cancer Institute-sponsored TAILORx study, which has
Conference Call Details
To access the live conference call today, August 5, at 4:30 p.m. Eastern Time via phone, please dial (877) 356-8064 from the United States and Canada or (706) 758-4314 internationally. The conference ID is 56195752. Please dial in approximately ten minutes prior to the start of the call. A telephone replay will be available beginning approximately one hour after the call through August 12 and may be accessed by dialing (800) 642-1687 from the United States and Canada or (706) 645-9291 internationally. The replay passcode is 56195752.
To access the live and subsequently archived webcast of the conference call, go to the Investor Relations section of the company's Web site at http://investor.genomichealth.com. Please connect to the web site at least 15 minutes prior to the call to allow for any software download that may be necessary.
About Genomic Health
Genomic Health, Inc. (Nasdaq: GHDX) is a life science company focused on the development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions. In 2004, Genomic Health launched its first test, Oncotype DX(R), which has been shown to predict the likelihood of breast cancer recurrence and the likelihood of chemotherapy benefit in a large portion of early-stage breast cancer patients. The company was founded in 2000 and is located in Redwood City, California. For more information, please visit http://www.genomichealth.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to our ability to further reduce our net loss; our ability to expand our efforts outside of the United States; our expectation that we will continue to invest in our product pipeline; the expected components of any future growth in our business; our plans to broaden the clinical utility of Oncotype DX to include reporting of quantitative HER2 scores; the results of a study regarding patients treated with aromatase inhibitors and our goals with respect to reporting results of that study; the timing of a validation study for a potential assay for colon cancer; the outcome of our study in Japan; our ability to develop a test for patients with renal cell carcinoma, clear cell type and the success of our collaboration with Pfizer; the outcome or success of planned or ongoing clinical trials and our expectations regarding potential clinical outcomes; the applicability of clinical study results to actual outcomes; the impact of the inclusion of Oncotype DX in treatment guidelines, additional clinical studies and our commercial efforts on continuing growth in adoption, reimbursement and revenue growth; our expectations regarding coverage for our test by Palmetto, the new Medicare administrative contractor for our test; and our revised 2008 financial guidance regarding expected range of test results delivered, our range of expected total revenue and our range of expected net loss. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: our ability to increase usage of our test; the risk that we may not obtain or maintain sufficient levels of reimbursement for our existing test and any future tests we may develop; the risks and uncertainties associated with the regulation of our tests by FDA; our ability to compete against third parties; our ability to develop and commercialize new tests; the results of clinical trials; unanticipated costs or delays in research and development efforts; our ability to obtain capital when needed; our history of operating losses; the results of clinical studies and the other risks set forth in our filings with the Securities and Exchange Commission, including the risks set forth in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2008. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward- looking statements.
NOTE: The Genomic Health logo, Oncotype, Oncotype DX and Recurrence
Score are trademarks or registered trademarks of Genomic Health, Inc. All
other trademarks and service marks are the property of their respective
(Financial statements below)
Genomic Health, Inc.
Condensed Consolidated Statements of Operations
(in thousands, except share and per share data)
For the Three Months For the Six Months Ended
Ended June 30, June 30,
2008 2007 2008 2007
Product revenues $26,327 $14,555 $49,682 $27,701
Contract revenues 1,456 135 1,541 1,077
Total revenues 27,783 14,690 51,223 28,778
Cost of product revenues 6,850 4,172 12,734 8,019
Research and development 7,322 5,224 13,728 10,394
Selling and marketing 11,827 8,740 24,194 16,893
General and administrative 6,225 4,186 12,130 8,275
Total operating expenses 32,224 22,322 62,786 43,581
Loss from operations (4,441) (7,632) (11,563) (14,803)
Other income (expense):
Interest income 448 612 1,069 1,128
Interest and other expense (106) (178) (239) (373)
Net loss $(4,099) $(7,198) $(10,733) $(14,048)
Basic and diluted net loss
per share $(0.15) $(0.28) $(0.38) $(0.55)
Shares used to compute
basic and diluted net
loss per share 28,262,407 26,141,476 28,239,908 25,355,685
Genomic Health, Inc.
Condensed Consolidated Balance Sheets
As of As of
Cash and cash equivalents $17,222 $39,164
Short-term investments 43,405 29,196
Accounts receivable, net 7,360 5,089
Prepaid expenses and other current
assets 4,649 3,105
Total current assets 72,636 76,554
Property and equipment, net 13,041 10,412
Restricted cash 500 500
Other assets 411 463
Total assets $86,588 $87,929
Accounts payable $1,913 $1,966
Accrued expenses and other current
liabilities 9,975 7,616
Deferred revenue 4,168 1,008
Notes payable, current 2,405 2,687
Notes payable, long-term 940 2,039
Other liabilities 1,695 1,447
Stockholders' equity 65,
|SOURCE Genomic Health, Inc.|
Copyright©2008 PR Newswire.
All rights reserved